Foundayo gets FDA OK

Eli Lilly’s Foundayo, a once-daily obesity pill, won U.S. Food and Drug Administration approval on April 1, giving the GLP-1 market a needle-free entrant. (fda.gov) The drug’s generic name is orforglipron, and the label covers adults with obesity or adults who are overweight and have at least one weight-related medical problem, alongside diet and exercise. (accessdata.fda.gov) GLP-1 drugs mimic a gut hormone that helps people feel fuller and eat less; Foundayo delivers that effect in tablet form once a day, without food or water restrictions. (fda.gov) (lilly.com) That dosing detail sets Foundayo apart from earlier oral GLP-1 medicines, which came with fasting rules that made timing part of the treatment. AJMC reported that convenience could reshape how doctors prescribe oral obesity drugs and how telehealth sellers distribute them. (ajmc.com) The approval moved unusually fast. The Food and Drug Administration said it cleared Foundayo 50 days after filing, 294 days ahead of the application’s January 20, 2027 PDUFA deadline, under the Commissioner’s National Priority Voucher pilot program. (fda.gov) In Lilly’s ATTAIN-1 trial, adults on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds on placebo. Across all treated participants, regardless of whether they completed treatment, average loss was 25 pounds versus 5.3 pounds on placebo. (lilly.com) (ajmc.com) The label still carries a boxed warning on thyroid C-cell tumors, and Foundayo is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The prescribing information also says using it with another GLP-1 receptor agonist is not recommended. (accessdata.fda.gov) Post-approval safety questions are still hanging over the launch. CNBC and Pharmaceutical Executive reported in mid-April that the Food and Drug Administration asked Lilly for more data on liver injury and cardiovascular events after approval, even as the drug reached the market. (cnbc.com) (pharmexec.com) Lilly began shipping Foundayo on April 6 and said on April 9 that the pill was available through LillyDirect, telehealth providers, and retail pharmacies nationwide. The company said eligible commercially insured patients could pay as little as $25 a month, while self-pay pricing starts at $149 a month at the lowest dose. (lilly.com 1) (lilly.com 2) For Lilly, the immediate test is no longer whether an obesity pill can win approval. It is whether a GLP-1 tablet that skips injections and timing rules can hold up under wider safety scrutiny while moving into telehealth carts and primary care offices. (fda.gov) (pharmexec.com)